Overview
- Artelo signed a Definitive Investigator-Initiated Study Agreement with Belfast Health and Social Care Trust to evaluate ART27.13 in glaucoma or ocular hypertension.
- The pilot will be a randomized, cross-over study sponsored by the Trust, conducted by the Northern Ireland Clinical Trials Unit, and led by Professor Augusto Azuara-Blanco of Queen’s University Belfast.
- Funding comes from Glaucoma UK and the HSC R&D Division, with Artelo supplying oral ART27.13 capsules as the investigational product.
- The protocol has ethics committee and UK MHRA approval, and first patient enrollment is anticipated in the second quarter of 2026.
- ART27.13 is a peripherally selective dual CB1/CB2 agonist intended to lower intraocular pressure without central psychotropic effects, and Artelo’s shares jumped over 40% pre-market on the news.